Cargando…
Lymphocyte predominance in blood, pleural fluid, and tumour stroma; a prognostic marker in pleural mesothelioma
BACKGROUND: As promising novel treatments develop for malignant pleural mesothelioma (MPM), early prognostication has become increasingly important. Circulating and local inflammatory cells are known to play a significant role in other tumour types. We assessed the proportion of lymphocyte populatio...
Autores principales: | De Fonseka, Duneesha, Arnold, David T., Morley, Anna J., Brett, Mary, Bhatt, Nidhi, Edey, Anthony, Daly, Richard, Bibby, Anna C., Maskell, Nick A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063088/ https://www.ncbi.nlm.nih.gov/pubmed/35501755 http://dx.doi.org/10.1186/s12890-022-01968-2 |
Ejemplares similares
-
Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial)
por: de Fonseka, Duneesha, et al.
Publicado: (2018) -
Ancillary Diagnostic Investigations in Malignant Pleural Mesothelioma
por: Dipper, Alex, et al.
Publicado: (2021) -
BTS guideline for the investigation and management of malignant pleural mesothelioma
por: Woolhouse, Ian, et al.
Publicado: (2018) -
Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre study
por: Bibby, Anna C., et al.
Publicado: (2017) -
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
por: Bibby, Anna C., et al.
Publicado: (2016)